Have a feature idea you'd love to see implemented?
Let us know!
RNAC Cartesian Therapeutics Inc
Price (delayed)
$16.62
Market cap
$422.4M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$52.75
Enterprise value
$217.85M
selecta biosciences, inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. selecta plans to combine its tolerogenic
Highlights
The quick ratio has soared by 143% YoY and by 124% QoQ
The company's equity has surged by 101% QoQ but it has shrunk by 99% YoY
RNAC's revenue is up by 39% year-on-year but it is down by 11% since the previous quarter
The company's debt rose by 40% YoY
RNAC's net income is down by 7% from the previous quarter
Key stats
What are the main financial stats of RNAC
Market
Valuations
Earnings
Shares outstanding
25.41M
Market cap
$422.4M
Enterprise value
$217.85M
Price to earnings (P/E)
N/A
Price to book (P/B)
537.62
Price to sales (P/S)
7.44
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.54
Revenue
$47.94M
EBIT
-$263.83M
EBITDA
-$260.65M
Free cash flow
-$48.41M
Per share
Balance sheet
Liquidity
EPS
-$52.75
Free cash flow per share
-$2.25
Book value per share
$0.03
Revenue per share
$2.23
TBVPS
$18.96
Total assets
$455.32M
Total liabilities
$454.56M
Debt
$14.65M
Equity
$752,000
Working capital
$207.73M
Debt to equity
19.48
Current ratio
10.7
Quick ratio
10.51
Net debt/EBITDA
0.78
Margins
Efficiency
Dividend
EBITDA margin
-543.7%
Gross margin
100%
Net margin
-510.7%
Operating margin
-111.6%
Return on assets
-69.5%
Return on equity
N/A
Return on invested capital
-161.7%
Return on capital employed
-60.8%
Return on sales
-550.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RNAC stock price
How has the Cartesian Therapeutics stock price performed over time
Intraday
-1.89%
1 week
-2.35%
1 month
-26.3%
1 year
-52.24%
YTD
-19.63%
QTD
3.1%
Financial performance
How have Cartesian Therapeutics's revenue and profit performed over time
Revenue
$47.94M
Gross profit
$47.94M
Operating income
-$53.5M
Net income
-$244.83M
Gross margin
100%
Net margin
-510.7%
RNAC's revenue is up by 39% year-on-year but it is down by 11% since the previous quarter
RNAC's gross profit is up by 39% YoY but it is down by 11% QoQ
RNAC's operating margin is up by 34% YoY but it is down by 23% from the previous quarter
The company's net margin fell by 20% QoQ
Growth
What is Cartesian Therapeutics's growth rate over time
Valuation
What is Cartesian Therapeutics stock price valuation
P/E
N/A
P/B
537.62
P/S
7.44
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.54
The company's equity has surged by 101% QoQ but it has shrunk by 99% YoY
RNAC's revenue is up by 39% year-on-year but it is down by 11% since the previous quarter
RNAC's P/S is 30% lower than its 5-year quarterly average of 10.7 but 26% higher than its last 4 quarters average of 5.9
Efficiency
How efficient is Cartesian Therapeutics business performance
The return on assets has dropped by 173% year-on-year but it has increased by 19% since the previous quarter
Cartesian Therapeutics's ROIC has plunged by 101% YoY but it has increased by 20% from the previous quarter
The company's return on sales fell by 20% QoQ
Dividends
What is RNAC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RNAC.
Financial health
How did Cartesian Therapeutics financials performed over time
The quick ratio has soared by 143% YoY and by 124% QoQ
RNAC's current ratio has soared by 137% YoY and by 124% QoQ
The company's equity has surged by 101% QoQ but it has shrunk by 99% YoY
The company's debt rose by 40% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.